



CIN: L24230GJ1972PLC002126

Website: www.torrentpharma.comEmail: investorservices@torrentpharma.com**TORRENT PHARMACEUTICALS LIMITED**

Registered Office:

Torrent House, Off Ashram Road,
Ahmedabad - 380 009, Gujarat, India.

Ph. : + 91 79 26599000

Fax : + 91 79 26582100

**Extract of Consolidated Financial Results
for the Quarter and Nine Months ended 31-Dec-2023**

[₹ in crores, except as stated otherwise]

Particulars	Quarter Ended 31-Dec-2023	Quarter Ended 31-Dec-2022 (Restated, Refer note 2)	Nine Months Ended 31-Dec-2023	Year Ended 31-Mar-2023
	Unaudited	Unaudited	Unaudited	Audited
Total Income from operations (net)	2732	2491	7983	9620
Net Profit / (Loss) for the period before tax and exceptional items	543	419	1633	1847
Net Profit / (Loss) for the period before tax and after exceptional items	631	419	1721	1847
Net Profit / (Loss) for the period after tax and exceptional items	443	292	1207	1245
Total Comprehensive Income (after tax)	442	251	1223	1108
Paid up Equity Share Capital	169.23	169.23	169.23	169.23
Other Equity excluding Revaluation Reserve				6029
Net worth	7151	6342	7151	6198
Paid up Debt Capital	786	1273	786	1273
Debt Equity Ratio (in times)	0.53	0.86	0.53	0.85
Earnings per share (of ₹ 5/- each) :				
Basic	13.10	8.63	35.67	36.79
Diluted	13.10	8.63	35.67	36.79
Debenture Redemption Reserve	71	107	71	107
Debt Service Coverage Ratio (in times)	2.21	1.65	1.54	1.89
Interest Service Coverage Ratio (in times)	9.08	6.33	8.01	7.55

Notes :

1 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :

[₹ in crores]

Particulars	Quarter Ended 31-Dec-2023	Quarter Ended 31-Dec-2022 (Restated, Refer note 2)	Nine Months Ended 31-Dec-2023	Year Ended 31-Mar-2023
Net income from operations	2123	1914	6390	7695
Profit before tax	430	342	1387	1577
Profit after tax	297	234	947	1052
Total Comprehensive Income (after tax)	284	213	964	974

2 The Company had acquired 100% shares of Curatio Health Care (I) Private Limited ('Curatio'), including its two subsidiaries, on 14-Oct-2022, for a total consideration of ₹ 2,000 crores. The Board of Directors of the Company, at its meeting held on 21-Dec-2022, had approved the Scheme of Arrangement in the nature of Amalgamation ('Scheme') of Curatio with the Company subject to requisite statutory and regulatory approvals. The scheme was filed and approved by the National Company Law Tribunal ('NCLT'), Ahmedabad Bench on 17-May-2023. The management had determined this as a subsequent adjusting event and hence the figures for the quarter ended 31-Dec-2022 was restated to give effect of amalgamation.

3 The Board of Directors in their meeting held on 02-Feb-2024, recommended an Interim equity dividend of ₹ 22/- per equity share.

4 The above is an extract of the detailed format of Financial Results for the quarter and Nine Months ended 31-Dec-2023 filed with Stock Exchanges under Regulation 33 & 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nseindia.com, www.bseindia.com and on the Company's website www.torrentpharma.com.

5 For the other line items referred in regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the Stock Exchange(s) and are available on www.nseindia.com, www.bseindia.com and can be accessed on the Company's website www.torrentpharma.com.

For TORRENT PHARMACEUTICALS LIMITED

SAMIR MEHTA
Executive Chairman
DIN : 00061903

Place : Ahmedabad, Gujarat
Date : 02-Feb-2024



CIN: L24230GJ1972PLC002126
Website: www.torrentpharma.com
Email: investorservices@torrentpharma.com

TORRENT PHARMACEUTICALS LIMITED

Registered Office:
Torrent House, Off Ashram Road,
Ahmedabad - 380 009, Gujarat, India.
Ph. : + 91 79 26599000
Fax : + 91 79 26582100

**Extract of Consolidated Financial Results
for the Quarter and Nine Months ended 31-Dec-2023**

[₹ in crores, except as stated otherwise]

Particulars	Quarter Ended 31-Dec-2023	Quarter Ended 31-Dec-2022 (Restated, Refer note 2)	Nine Months Ended 31-Dec-2023	Year Ended 31-Mar-2023
	Unaudited	Unaudited	Unaudited	Audited
Total Income from operations (net)	2732	2491	7983	9620
Net Profit / (Loss) for the period before tax and exceptional items	543	419	1633	1847
Net Profit / (Loss) for the period before tax and after exceptional items	631	419	1721	1847
Net Profit / (Loss) for the period after tax and exceptional items	443	292	1207	1245
Total Comprehensive Income (after tax)	442	251	1223	1108
Paid up Equity Share Capital	169.23	169.23	169.23	169.23
Other Equity excluding Revaluation Reserve				6029
Net worth	7151	6342	7151	6198
Paid up Debt Capital	786	1273	786	1273
Debt Equity Ratio (in times)	0.53	0.86	0.53	0.85
Earnings per share (of ₹ 5/- each) :				
Basic	13.10	8.63	35.67	36.79
Diluted	13.10	8.63	35.67	36.79
Debenture Redemption Reserve	71	107	71	107
Debt Service Coverage Ratio (in times)	2.21	1.65	1.54	1.89
Interest Service Coverage Ratio (in times)	9.08	6.33	8.01	7.55

Notes :

1 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :

[₹ in crores]

Particulars	Quarter Ended 31-Dec-2023	Quarter Ended 31-Dec-2022 (Restated, Refer note 2)	Nine Months Ended 31-Dec-2023	Year Ended 31-Mar-2023
Net income from operations	2123	1914	6390	7695
Profit before tax	430	342	1387	1577
Profit after tax	297	234	947	1052
Total Comprehensive Income (after tax)	284	213	964	974

- 2 The Company had acquired 100% shares of Curatio Health Care (I) Private Limited ('Curatio'), including its two subsidiaries, on 14-Oct-2022, for a total consideration of ₹ 2,000 crores. The Board of Directors of the Company, at its meeting held on 21-Dec-2022, had approved the Scheme of Arrangement in the nature of Amalgamation ('Scheme') of Curatio with the Company subject to requisite statutory and regulatory approvals. The scheme was filed and approved by the National Company Law Tribunal ('NCLT'), Ahmedabad Bench on 17-May-2023. The management had determined this as a subsequent adjusting event and hence the figures for the quarter ended 31-Dec-2022 was restated to give effect of amalgamation.
- 3 The Board of Directors in their meeting held on 02-Feb-2024, recommended an Interim equity dividend of ₹ 22/- per equity share.
- 4 The above is an extract of the detailed format of Financial Results for the quarter and Nine Months ended 31-Dec-2023 filed with Stock Exchanges under Regulation 33 & 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nseindia.com, www.bseindia.com and on the Company's website www.torrentpharma.com.
- 5 For the other line items referred in regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertinent disclosures have been made to the Stock Exchange(s) and are available on www.nseindia.com, www.bseindia.com and can be accessed on the Company's website www.torrentpharma.com.

For TORRENT PHARMACEUTICALS LIMITED

SAMIR MEHTA
Executive Chairman
DIN : 00061903

Place : Ahmedabad, Gujarat
Date : 02-Feb-2024